| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018 | 1230 | 2018 |
| Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi Nature reviews Clinical oncology 16 (11), 703-715, 2019 | 1033 | 2019 |
| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 924 | 2014 |
| Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ... JAMA oncology 2 (1), 46-54, 2016 | 859 | 2016 |
| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 773 | 2022 |
| Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 J Wang, MF Sanmamed, I Datar, TT Su, L Ji, J Sun, L Chen, Y Chen, ... Cell 176 (1), 334-347. e12, 2019 | 669 | 2019 |
| Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade Z Wang, EG Aguilar, JI Luna, C Dunai, LT Khuat, CT Le, A Mirsoian, ... Nature medicine 25 (1), 141-151, 2019 | 626 | 2019 |
| Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer S Gettinger, J Choi, K Hastings, A Truini, I Datar, R Sowell, A Wurtz, ... Cancer discovery 7 (12), 1420-1435, 2017 | 603 | 2017 |
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma KA Schalper, ME Rodriguez-Ruiz, R Diez-Valle, A López-Janeiro, ... Nature medicine 25 (3), 470-476, 2019 | 535 | 2019 |
| Immunotherapy in non–small cell lung cancer: facts and hopes DB Doroshow, MF Sanmamed, K Hastings, K Politi, DL Rimm, L Chen, ... Clinical Cancer Research 25 (15), 4592-4602, 2019 | 533 | 2019 |
| In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ... Clinical cancer research 20 (10), 2773-2782, 2014 | 533 | 2014 |
| Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis S Lu, JE Stein, DL Rimm, DW Wang, JM Bell, DB Johnson, JA Sosman, ... JAMA oncology 5 (8), 1195-1204, 2019 | 515 | 2019 |
| CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ... Immunity 52 (5), 856-871. e8, 2020 | 472 | 2020 |
| PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer H Wimberly, JR Brown, K Schalper, H Haack, MR Silver, C Nixon, ... Cancer immunology research 3 (4), 326-332, 2015 | 412 | 2015 |
| Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial SB Goldberg, KA Schalper, SN Gettinger, A Mahajan, RS Herbst, ... The Lancet Oncology 21 (5), 655-663, 2020 | 395 | 2020 |
| Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients MF Sanmamed, JL Perez-Gracia, KA Schalper, JP Fusco, A Gonzalez, ... Annals of Oncology 28 (8), 1988-1995, 2017 | 395 | 2017 |
| Objective measurement and clinical significance of TILs in non–small cell lung cancer KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ... Journal of the National Cancer Institute 107 (3), dju435, 2015 | 395 | 2015 |
| Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors KA Schalper, M Carleton, M Zhou, T Chen, Y Feng, SP Huang, AM Walsh, ... Nature medicine 26 (5), 688-692, 2020 | 347 | 2020 |
| Interleukin-8 in cancer pathogenesis, treatment and follow-up C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz, Á Teijeira, C Oñate, ... Cancer treatment reviews 60, 24-31, 2017 | 319 | 2017 |
| Oncolytic virus immunotherapy: future prospects for oncology J Raja, JM Ludwig, SN Gettinger, KA Schalper, HS Kim Journal for immunotherapy of cancer 6, 1-13, 2018 | 294 | 2018 |
